Disc Medicine Q2 net loss $26.4M; cash $500.9M; positive EHA data across pipeline

Disc Medicine, Inc.

2024-Q2 EPS reported -$2.11

Net loss of $26.4M for Q2 2024 vs $15.9M in Q2 2023; R&D expenses rose to $23.5M.
Cash, cash equivalents & marketable securities of $500.9M as of June 30, 2024; raised $178M in June offering.
Presented positive data for bitopertin (EPP), DISC-0974 (anemia of MF), and DISC-3405 (hepcidin) at EHA 2024.
Expects regulatory interactions for bitopertin and DISC-0974 in H2 2024; DISC-3405 MAD data also expected in H2.
Cash runway expected to fund operations well into 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.